Artivion, Inc. (AORT)
Market Cap | 510.27M |
Revenue (ttm) | 313.79M |
Net Income (ttm) | -19.19M |
Shares Out | 42.10M |
EPS (ttm) | -0.48 |
PE Ratio | n/a |
Forward PE | 357.14 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 167,063 |
Open | 12.30 |
Previous Close | 12.03 |
Day's Range | 11.96 - 12.49 |
52-Week Range | 9.64 - 23.43 |
Beta | 1.39 |
Analysts | Buy |
Price Target | 23.03 (+90.02%) |
Earnings Date | May 4, 2023 |
About AORT
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment... [Read more]
Financial Performance
In 2022, Artivion's revenue was $313.79 million, an increase of 5.00% compared to the previous year's $298.84 million. Losses were -$19.19 million, 29.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AORT stock is "Buy." The 12-month stock price forecast is $23.03, which is an increase of 90.02% from the latest price.
News

Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference
ATLANTA , March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the...

Artivion (AORT) Q4 Earnings Surpass Estimates
Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Artivion Reports Fourth Quarter and Full Year 2022 Financial Results
Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth quarter of 2021, flat on a GAAP basis and an increase ...

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results
ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 fin...

Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?
Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Think Artivion (AORT) Could Surge 79%: Read This Before Placing a Bet
The consensus price target hints at a 79.4% upside potential for Artivion (AORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

Wall Street Analysts Predict a 173% Upside in Artivion (AORT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 173.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the posi...

Artivion to Participate in Upcoming Investor Conferences
ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i...

Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates
Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Artivion Reports Third Quarter 2022 Financial Results
Third Quarter and Recent Business Highlights: Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11...

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results
ATLANTA , Oct. 20, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results...

Elizabeth Hoff Joins Artivion Board of Directors
ATLANTA , Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A.

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial
Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ --- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery ...

Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference
ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deu...

Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
ATLANTA , Aug. 24, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upc...

Artivion Reports Second Quarter 2022 Financial Results
ATLANTA , Aug. 4, 2022 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, ...

What Makes Artivion (AORT) a New Buy Stock
Artivion (AORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Artivion Initiates Enrollment in PERSEVERE Clinical Trial
Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA Submission ATLANTA , July 27, 2022 /PRNewswire/...

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2022 Financial Results
ATLANTA , July 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2022 financial result...

Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?
Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

Artivion to Participate in the UBS 2022 Global Healthcare Conference
ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming U...

Artivion Reports First Quarter 2022 Financial Results
Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis ATLAN...

ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results
ATLANTA, April 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results...

Artivion to Participate in the 21st Annual Needham Virtual Healthcare Conference
ATLANTA, March 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming ...

Artivion Publishes Inaugural Corporate Responsibility Report
ATLANTA, March 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Re...